logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Norepinephrine Reuptake Inhibitor class drugs

    FiltersReset Filters
    4 results

    • atomoxetine

      (Atomoxetine)
      Aurobindo Pharma Limited
      Usage: Atomoxetine capsules are indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in pediatric patients aged 6-18 and adults. They are part of a comprehensive treatment program that may include psychological and educational measures, and are not intended for patients with ADHD symptoms secondary to environmental factors or other psychiatric conditions.

    • atomoxetine

      (Atomoxetine)
      Rising Pharma Holdings, Inc.
      Usage: Atomoxetine capsules are indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in pediatric patients (ages 6-18) and adults. It is part of a comprehensive treatment program, which may include other psychological, educational, and social interventions. It is not intended for symptoms due to environmental factors or primary psychiatric disorders.

    • atomoxetine

      (atomoxetine)
      Glenmark Pharmaceuticals Inc., USA
      Usage: Atomoxetine capsules are indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in pediatric patients (ages 6-18) and adults. It is part of a comprehensive treatment program which may include psychological and educational measures, and is not intended for patients with symptoms due to environmental factors or other psychiatric disorders.

    • qelbree

      (viloxazine hydrochloride)
      Supernus Pharmaceuticals, Inc
      Usage: Qelbree is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in individuals aged 6 years and older, including adults.